Physician profile
Thea Floyd
NPI 1073054953
$22,545.62
in general payments reported to CMS, 2019-2025
38 companies · $5,214 in 2025
The $5,214 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,996 · 2022: $5,396 · 2023: $1,841 · 2024: $5,097 · 2025: $5,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,267 · Consulting Fee: $3,410 · Travel and Lodging: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,266.73 |
| Consulting Fee | $3,410.00 |
| Travel and Lodging | $2,476.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15,584.22 | 2021-2025 | Epclusa, Descovy |
| Abbvie INC. | $2,303.87 | 2021-2025 | |
| Novo Nordisk INC | $986.19 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $500.98 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $424.74 | 2022-2025 | |
| Lilly USA, LLC | $283.54 | 2021-2025 | Mounjaro, Trulicity, Emgality |
| Amgen INC. | $265.60 | 2021-2025 | Repatha, Otezla, Repatha |
| Alkermes, INC. | $262.41 | 2021-2025 | Aristada, Vivitrol, Vivitrol |
| Astrazeneca Pharmaceuticals LP | $250.66 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.25 | 2021-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $197.41 | 2023-2025 | Auvelity |
| Lundbeck LLC | $117.98 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.17 | 2021-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $115.16 | 2021-2023 | Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $107.78 | 2022-2024 | Spravato |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thea Floyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.